PhD in cancer and immunology, The Hebrew University of Jerusalem, Israel.Post doctorate, Singapore Immunology Network (SIgN), SingaporePost doctorate, Shenzhen Bay Laboratory, China
My research in the lab focuses on understanding the mechanisms underlying pulmonary fibrosis and is dedicated to identifying novel therapeutic strategies. Pulmonary fibrosis is a progressive and often fatal disease marked by irreversible scarring of lung tissue. While current treatments, such as pirfenidone and nintedanib, can slow disease progression, they neither reverse the fibrosis nor provide a cure. Advancing our understanding of this condition is essential for developing more effective therapies, improving patient outcomes, and alleviating the growing healthcare burden associated with chronic lung diseases.
Lei Xia#, Anastasia Komissaroval#, Arielle Jacover#, Yehuda Shovman#, Sebastian ArcilaBarrera, Sharona Tornovsky, Milsee Mol Jaya Prakashan, Abdelmajeed Nasereddin , Inbar Plaschkes , Yuval Nevo, Shiff Idit, Oshri Yosefov-Levi, Tamara Izhiman, Eleonora Medvedev, Elad Eilon, Asaf Wilensky , Simon Yona , Oren Parnas. Systematic identification of gene combinations to target in innate immune cells to enhance T cell activation. Nature Communications (2023) 4(1):6295
L Xia#, X Xiao#, WL Liu, Y Song, TJJ Liu, YJ Li, E Zacksenhaus, XJ Hao and Y Ben-David. Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling. Oncogene (2018) 37, 323–331.
Tangjingjun Liu#, Lei Xia#, Yao Yao, Chen Yan , Yanhua Fan, Babu Gajendran, Jue Yang, You Jun Li , Juan Chen, Jorge Filmus, David E Spaner, Eldad Zacksenhaus, Xiaojiang Hao and Yaacov Ben-David. Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis. Cell Death and Disease (2019) 10:117
